In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

TORONTO, le 10 juin 2019 /CNW/ - Les résultats détaillés de REWIND, l'étude sur l'issue cardiovasculaire portant sur Trulicity ® (dulaglutide), ont montré une réduction significative de 12 ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024/ PRNewswire/-- Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.

Once-weekly dulaglutide, an investigational, long-acting GLP-1 receptor agonist being studied as a treatment for type 2 diabetes, has been submitted to the U.S. Food and Drug Administration (FDA ...

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0 ...

Adobe Stock ESRD or an eGFR reduction of at least 40% occurred in 5.2% of those taking 1.5 mg dulaglutide, 8.4% of those taking 0.75 mg dulaglutide and 10.8% of those taking insulin glargine.